Business
Clene to Present at Upcoming October Conferences
SALT LAKE CITY, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene
About this update from Clene Inc.
SALT LAKE CITY , Oct. 09, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. , a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will participate in the following investor conferences in October. 2024 Maxim Healthcare Virtual Summit Date: October 15-17, 2024 Location: VirtualPresentation: October 15, 2024 , at 2:30 p.m. E.T. Format: Fireside Presentation and 1x1 meetingsAttendance: Sign up to become an M-Vest member The ThinkEquity Conference 2024 Dates: October 30, 2024 Location: New York, New York , Mandarin Oriental Hotel Presentation: October 30, 2024 , at 3:30 p.m. E.T. Format: Presentation and 1x1 meetingsWebcast Link: https://wsw.com/webcast/tep25/clnn/1673136 About Clene Clene Inc. , (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. , is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah , with R&D and manufacturing operations in Maryland . For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn . Contacts: Media Contact Ignacio Guerrero-Ros , Ph.D., or David Schull Russo Partners, LLC [email protected] [email protected] (858) 717-2310 Investor Contact Kevin Gardner LifeSci Advisors [email protected] 617-283-2856 Source: Clene Inc.